Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 150,164	$ 198,955
Short-term investments	887,152	862,941
Accounts receivable	29,156	38,889
Inventory	16,808	15,292
Other current assets	15,771	21,928
Total current assets	1,099,051	1,138,005
Long-term investments	96,093	136,662
Property, plant and equipment, net	58,510	59,662
Operating lease right-of-use assets	124,971	126,476
Goodwill	76,501	76,501
Other assets	1,435	1,461
Total assets	1,456,561	1,538,767
Current liabilities:
Accounts payable	22,434	22,139
Accrued compensation	23,513	14,532
Accrued clinical trial expenses	41,028	44,207
Accrued contract manufacturing expenses	6,057	11,310
Other accrued expenses	14,833	9,676
Operating lease liabilities, current portion	15,768	13,915
Total current liabilities	123,633	115,779
Operating lease liabilities, less current portion	134,556	136,373
Development derivative liability	4,597	0
Liabilities related to the sales of future royalties, net	195,139	200,340
Other long-term liabilities	4,130	8,980
Total liabilities	462,055	461,472
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at March 31, 2021 or December 31, 2020	0	0
Common stock, $0.0001 par value; 300,000 shares authorized; 182,290 shares and 180,091 shares outstanding at March 31, 2021 and December 31, 2020, respectively	18	18
Capital in excess of par value	3,429,734	3,388,730
Accumulated other comprehensive loss	(3,121)	(2,295)
Accumulated deficit	(2,432,125)	(2,309,158)
Total stockholders’ equity	994,506	1,077,295
Total liabilities and stockholders’ equity	$ 1,456,561	$ 1,538,767